Stifel Nicolaus assumed coverage on shares of Repare Therapeutics (NASDAQ:RPTX) in a research note issued to investors on Wednesday, Price Targets.com reports. The brokerage issued a buy rating and a $48.00 price objective on the stock.
A number of other equities analysts also recently weighed in on the company. Guggenheim assumed coverage on Repare Therapeutics in a research report on Monday, June 28th. They set a buy rating and a $46.00 price target on the stock. Morgan Stanley boosted their price target on Repare Therapeutics from $45.00 to $47.00 and gave the stock an overweight rating in a research report on Monday, August 16th. HC Wainwright initiated coverage on Repare Therapeutics in a research report on Monday, September 13th. They issued a buy rating and a $54.00 target price on the stock. Finally, Zacks Investment Research downgraded Repare Therapeutics from a hold rating to a sell rating in a research report on Saturday, September 11th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of Buy and a consensus target price of $47.33.
Shares of NASDAQ RPTX opened at $27.63 on Wednesday. The business’s 50 day moving average price is $32.84 and its two-hundred day moving average price is $32.26. The company has a market cap of $1.03 billion, a PE ratio of -13.35 and a beta of -0.35. Repare Therapeutics has a twelve month low of $21.76 and a twelve month high of $46.44.
In related news, Director Todd Foley sold 7,270 shares of the business’s stock in a transaction that occurred on Monday, June 28th. The stock was sold at an average price of $34.18, for a total value of $248,488.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Orbimed Advisors Llc sold 7,082 shares of the business’s stock in a transaction that occurred on Wednesday, August 25th. The shares were sold at an average price of $34.34, for a total value of $243,195.88. The disclosure for this sale can be found here. Insiders sold 205,175 shares of company stock worth $6,933,616 in the last ninety days. 33.60% of the stock is owned by company insiders.
Several hedge funds have recently modified their holdings of RPTX. Price T Rowe Associates Inc. MD boosted its stake in shares of Repare Therapeutics by 2,044.2% in the second quarter. Price T Rowe Associates Inc. MD now owns 1,176,004 shares of the company’s stock valued at $36,668,000 after buying an additional 1,121,157 shares during the period. BVF Inc. IL lifted its stake in Repare Therapeutics by 25.2% during the first quarter. BVF Inc. IL now owns 3,722,398 shares of the company’s stock worth $114,240,000 after purchasing an additional 750,207 shares during the last quarter. ARK Investment Management LLC lifted its stake in Repare Therapeutics by 113.8% during the first quarter. ARK Investment Management LLC now owns 1,358,589 shares of the company’s stock worth $41,695,000 after purchasing an additional 723,196 shares during the last quarter. Great Point Partners LLC bought a new stake in Repare Therapeutics during the second quarter worth $13,597,000. Finally, Logos Global Management LP lifted its stake in Repare Therapeutics by 33.0% during the first quarter. Logos Global Management LP now owns 900,000 shares of the company’s stock worth $27,621,000 after purchasing an additional 223,106 shares during the last quarter. Institutional investors and hedge funds own 71.52% of the company’s stock.
Repare Therapeutics Company Profile
Repare Therapeutics Inc, a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair.
Recommended Story: Is it Safe to Invest in Commodities?
Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.